NewAmsterdam Pharma (NAMS) Operating Expenses (2023 - 2026)

NewAmsterdam Pharma has reported Operating Expenses for 4 years, with the latest figure at $61.5 million in Q1 2026.

• Quarterly Operating Expenses fell 14.52% year-over-year to $61.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $237.7 million (changed 0.37% YoY) and the FY2025 annual result came in at $248.2 million, up 11.87% from the prior year.
• Operating Expenses declined to $61.5 million in Q1 2026 per NAMS's latest filing, from $66.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $71.9 million in Q1 2025 and troughed at $44.2 million in Q2 2023.
• A 4-year average of $56.0 million and a median of $54.9 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses climbed 26.41% in 2025, then declined 14.52% in 2026.
• Over 4 years, Operating Expenses stood at $51.9 million in 2023, then rose by 7.95% to $56.0 million in 2024, then rose by 17.88% to $66.0 million in 2025, then declined by 6.9% to $61.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $61.5 million, $66.0 million, and $55.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.